Oxford Nanopore Technologies Annual Report and Accounts 2024

Our goal: to enable the analysis of anything, by anyone, anywhere.

Introduction

Oxford Nanopore Technologies is a leader in developing a new generation of nanopore-based sensing technology. This innovative platform is revolutionizing DNA and RNA analysis, offering information-rich, rapid, accessible, and affordable solutions. The company's technology is also being advanced for the analysis of proteins and metabolites, broadening its impact across various scientific and industrial sectors.

Key Highlights from 2024

  • Achieved strong revenue growth, in line with guidance, with significant momentum across all regions.
  • Expanded collaborations with key partners like Precision Health and Lonza, driving innovation in areas such as mRNA product analysis.
  • Launched new products including PromethION 2 Integrated (P2i) and MinION MK1D, alongside advancements in regulated product pipelines.
  • Published research papers highlighting the growing utility and impact of Oxford Nanopore's technology in fields like cancer, human genetics, and infectious diseases.
  • Strengthened the management team and Board with experienced professionals to support future growth and strategic objectives.

Company Vision and Strategy

Oxford Nanopore's vision is to empower people to explore and answer biological questions through its transformative technology. The company focuses on making biological analysis more accessible and affordable, breaking down historical barriers to entry. Key strategic priorities include expanding into new markets such as BioPharma, Clinical, and Applied Industrial sectors, while continuing to innovate and enhance its core sequencing platform.

Market Opportunity

The company operates in substantial and growing markets, with a long-term vision to enable distributed analyses across various systems and supply chains. The total addressable market is estimated to be over $150 billion, driven by the increasing demand for molecular insights in healthcare, biopharma, environmental monitoring, and other industries. Oxford Nanopore's differentiated technology positions it to capture a significant share of this expanding market.

PDF preview unavailable. Download the PDF instead.

7894-ont-ar24-interactive-25-07-07-v2 Adobe InDesign 19.5 (Macintosh) Adobe PDF Library 17.0

Related Documents

Preview Oxford Nanopore Technologies 2025 Interim Results Presentation - Financial Performance and Strategic Update
Detailed overview of Oxford Nanopore Technologies' financial performance for the first half of 2025, including revenue growth, profitability improvements, strategic progress across key markets, and future guidance. Features insights into R&D, operational efficiency, and platform benefits.
Preview PromethION 2 Solo Quick Start Guide
A quick start guide for setting up and verifying the PromethION 2 Solo device, including pre-installation checks, device setup, hardware checks, and power-off procedures.
Preview Oxford Nanopore Technologies Sustainability Report FY 2024
Discover Oxford Nanopore Technologies' commitment to sustainability with their FY 2024 report, detailing their impact on Product, People, and Planet. Learn about their vision, mission, values, and how their innovative nanopore sequencing technology is driving advancements in science, health, agriculture, and conservation.
Preview Direct-from-Colony Microbial Sequencing: Rapid Salmonella Serotyping with Oxford Nanopore
A protocol overview for direct-from-colony microbial sequencing of Salmonella using Oxford Nanopore technologies, enabling rapid serotyping and genomic analysis.
Preview Oxford Nanopore Amplicon Sequencing: Rapid, Scalable Full-Length Validation Workflow
Learn about Oxford Nanopore's rapid and scalable end-to-end workflow for full-length amplicon sequencing, ideal for biopharmaceutical research and synthetic biology applications. Covers DNA extraction, library preparation, sequencing, and analysis.
Preview Oxford Nanopore Technologies plc Interim Results H1 2025: Strong Growth and Reaffirmed Guidance
Oxford Nanopore Technologies plc announces its interim results for the six months ended 30 June 2025, detailing strong first-half performance, revenue growth ahead of expectations, improved EBITDA, and reaffirmed financial guidance. The report covers operational and strategic achievements, including innovation and partnerships.
Preview Oxford Nanopore Large Cohort Sequencing Workflow for Clinical Research
Accelerate clinical research with Oxford Nanopore's PromethION 24 platform. This guide details a comprehensive workflow for large cohort genomic and epigenomic analysis, from DNA extraction to variant calling.
Preview Oxford Nanopore Service Provider Programme: Transform Services with Multiomic Insights
Learn how Oxford Nanopore's Service Provider Programme empowers labs to deliver advanced multiomic insights, attract service projects, and scale innovation with their cutting-edge sequencing technology and EPI2ME platform.